3.13
+0.17(+5.74%)
Currency In USD
| Previous Close | 2.96 |
| Open | 2.97 |
| Day High | 3.15 |
| Day Low | 2.92 |
| 52-Week High | 4.08 |
| 52-Week Low | 1.24 |
| Volume | 4.78M |
| Average Volume | 4.25M |
| Market Cap | 829.9M |
| PE | -17.39 |
| EPS | -0.18 |
| Moving Average 50 Days | 3.49 |
| Moving Average 200 Days | 2.59 |
| Change | 0.17 |
If you invested $1000 in Akebia Therapeutics, Inc. (AKBA) 10 years ago, it would be worth $275.53 as of September 09, 2025 at a share price of $3.13. Whereas If you bought $1000 worth of Akebia Therapeutics, Inc. (AKBA) shares 5 years ago, it would be worth $1,181.13 as of September 09, 2025 at a share price of $3.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akebia Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 28, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participa
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
GlobeNewswire Inc.
Aug 21, 2025 12:00 PM GMT
CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and Innovative Renal Care (IRC
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executi